Edmond DE Rothschild Holding S.A. bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund bought 900,000 shares of the company's stock, valued at approximately $17,199,000.
Other institutional investors also recently added to or reduced their stakes in the company. AssuredPartners Investment Advisors LLC purchased a new stake in Kenvue during the second quarter worth about $625,000. Johnson Financial Group Inc. purchased a new position in Kenvue in the second quarter valued at about $26,000. Tocqueville Asset Management L.P. purchased a new position in Kenvue in the second quarter valued at about $30,302,000. NewEdge Wealth LLC bought a new position in shares of Kenvue during the 2nd quarter valued at approximately $1,026,000. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Kenvue during the 2nd quarter worth approximately $1,503,000. Institutional investors own 97.64% of the company's stock.
Analysts Set New Price Targets
KVUE has been the topic of several research analyst reports. Wall Street Zen downgraded Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research note on Monday, June 15th. Barclays upped their price target on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 21st. UBS Group cut their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Finally, Zacks Research lowered Kenvue from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $19.27.
Get Our Latest Report on Kenvue
Kenvue Stock Up 1.9%
KVUE opened at $19.16 on Thursday. The company has a 50 day moving average of $19.02 and a 200 day moving average of $18.18. The company has a market cap of $36.80 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 1.35 and a beta of 0.47. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $21.84. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company's revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.29 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. This is a boost from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date is Wednesday, August 12th. Kenvue's dividend payout ratio (DPR) is presently 96.55%.
About Kenvue
(
Free Report)
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Further Reading
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
